Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLS001 exploratory study in bullous keratopathy
jRCTa031210199Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of omiganan in bullous keratopathy (PBK), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Systemic safety and Ophthalmologic safety. Started Jul 2022; status: active, not recruiting.
02
Drugs
omiganan
03
Conditions
bullous keratopathy (PBK)
Beyond the preview
Go deeper on jRCTa031210199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTa031210199.